Grace Therapeutics, Inc.

Grace Therapeutics, Inc. reported a net loss of $2.3 million for Q3 2026 (period ending December 31, 2025), driven by a loss from operating activities of $2.4 million. Operating expenses totaled $2.5 million, consisting of $2.0 million in general and administrative expenses and $462,000 in research and development expenses (net of government assistance). The company generated $134,000 in total other income, primarily from interest and other income ($170,000) and a change in fair value of derivative warrant liabilities ($40,000), partially offset by foreign exchange loss ($4,000). Cash flow from operations was negative $7.2 million, but financing activities provided $3.7 million from common warrant exercises, resulting in a net decrease in cash of $3.5 million. The balance sheet shows $68.5 million in total assets, including $19.2 million in current assets (with $18.7 million in cash and cash equivalents) and $41.1 million in intangible assets. Total liabilities are $3.6 million, with stockholders' equity at $64.9 million. The company's cash position decreased from $22.1 million to $18.7 million during the quarter.

Key Takeaways